Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: A cross-sectional study

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 6, 2015, Pages 679-685

  Sulyok, Mihály ^a   Makara, Mihály ^c   Rupnik, Zsófia ^d   Ferenci, Tamás ^f   Újhelyi, Eszter ^e   Kormos, Luca ^d   Gerlei, Zsuzsanna ^b   Szlávik, János ^d   Horváth, Gábor ^g   Vályi Nagy, István ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Center for Hepatology   (Hungary)

^d Center for HIV   (Hungary)

^e Immunology and Molecular Diagnostics Laboratory   (Hungary)

^f ÓBUDA UNIVERSITY   (Hungary)

^g Hepatology Center of Buda   (Hungary)

Author keywords

elasticity imaging techniques; fatty liver; HIV infections; multivariate analysis

Indexed keywords

ABACAVIR; BLOOD CLOTTING FACTOR; CD8 ANTIGEN; CHOLESTEROL; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE PERCENTAGE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED ATTENUATION PARAMETER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELASTOGRAPH; ELASTOGRAPHY; FATTY LIVER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOLOGICAL PARAMETERS; LIPID STORAGE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; METABOLIC PARAMETERS; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS ATTENUATION; AGED; BLOOD; BODY MASS; ECHOGRAPHY; ELASTICITY; HIV INFECTIONS; MIDDLE AGED; SURVIVOR; TIME; YOUNG ADULT;

ADULT; AGED; BODY MASS INDEX; CD4-CD8 RATIO; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DARUNAVIR; DIABETES MELLITUS; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE; SURVIVORS; TIME FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84957638076     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000339     Document Type: Article

References (30)

1. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
2. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50:464-473.
3. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-372.
4. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: Prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250-257.
5. Shirley DK, Kaner RJ, Glesby MJ. Effects of smoking on non-AIDSrelated morbidity in HIV-infected patients. Clin Infect Dis 2013; 57:275-282.
6. Garey L, Bakhshaie J, Sharp C, Neighbors C, Zvolensky MJ, Gonzalez A. Anxiety, depression, and HIV symptoms among persons living with HIV/AIDS: The role of hazardous drinking. AIDS Care 2015; 27:80-85.
7. Chibanda D, Benjamin L, Weiss HA, Abas M. Mental, neurological, and substance use disorders in people living with HIV/AIDS in low-and middle-income countries. J Acquir Immune Defic Syndr 2014; 67 (Suppl 1): S54-S67.
8. Blank MB, Himelhoch S, Walkup J, Eisenberg MM. Treatment considerations for HIV-infected individuals with severe mental illness. Curr HIV/AIDS Rep 2013; 10:371-379.
9. Bongiovanni M, Tordato F. Steatohepatitis in HIV-infected subjects: Pathogenesis, clinical impact and implications in clinical management. Curr HIV Res 2007; 5:490-498.
10. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterol 2014; 5:211-218.
11. Nalbantoglu IL, Brunt EM. Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20:9026-9037.
12. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32:477-481.
13. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
14. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51:433-445.
15. Sasso M, Beaugrand M, De Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36:1825-1835.
16. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36:13-20.
17. Recio E, Cifuentes C, Macías J, Mira JA, Parra-Sánchez M, Rivero-Juárez A, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol 2013; 25:905-911.
18. Macías J, González J, Tural C, Ortega-González E, Pulido F, Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIVinfected patients. AIDS 2014; 28:1279-1287.
19. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
20. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140:809-817.
21. Macías J, Berenguer J, Japón MA, Girón-González JA, Rivero A, López-Cortés LF, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56:1261-1270.
22. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026-1032.
23. Li Vecchi V, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, La Spada E, et al. Non-invasive assessment of liver steatosis and fibrosis in HIV/HCV-and HCV-infected patients. Ann Hepatol 2013; 12:740-748.
24. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta-analysis of the risk factors. Hepatology 2010; 52:71-78.
25. Li Vecchi V, Soresi M, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, et al. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection. Int J Infect Dis 2012; 16:e397-e402.
26. Ingiliz P, Valantin MA, Duvivier C, Medja F, Dominguez S, Charlotte F, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-442.
27. WHO Management of Substance Abuse Unit. Appendix I: Alcohol consumption, 2014. Available at: Http://www.who.int/substance-abuse/publications/global-alcohol-report/msb-gsr-2014-3.pdf?ua=1. [Accessed 15 October 2014].
28. Xiao J, Han N, Yang D, Zhao H. Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: Characteristics and independent risk factors. Virol J 2013; 10:261.
29. Saracino A, Bruno G, Scudeller L, Volpe A, Caricato P, Ladisa N, et al. Chronic inflammation in a Long-term cohort of HIV-Infected patients according to the normalization of the CD4:CD8 ratio. AIDS Res Hum Retroviruses 2014; 30:1178-1184. doi: 10.1089/aid.2014.0080.
30. Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, et al. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. BMC Res Notes 2012; 5:180.